Overview

* LivaNova Q2 2025 revenue rises 10.7%, beating analyst expectations, per LSEG data

* Adjusted EPS of $1.05 beats estimates, reflecting strong operational performance

* Company raises full-year 2025 guidance for revenue, adjusted EPS and free cash flow

Outlook

* LivaNova ( LIVN ) raises 2025 revenue growth guidance to 8%-9% constant-currency

* Company expects 2025 adjusted EPS between $3.70 and $3.80

* LivaNova ( LIVN ) projects 2025 adjusted free cash flow of $140 mln to $160 mln

* Company sees foreign currency as a tailwind of approximately 1% for 2025

Result Drivers

* CARDIOPULMONARY DEMAND - Strong demand for consumables and Essenz Perfusion System drove Cardiopulmonary revenue growth

* NEUROMODULATION PERFORMANCE - Solid performance across all regions contributed to Neuromodulation revenue increase

* OPERATING MARGIN EXPANSION - Disciplined execution led to meaningful operating margin expansion, per CEO Vladimir Makatsaria

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $352.50 $332.30

Revenue mln mln (8

Analysts

)

Q2 Beat $1.05 $0.86 (8

Adjusted Analysts

EPS )

Q2 EPS $0.5

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for LivaNova PLC ( LIVN ) is $58.00, about 26.5% above its August 5 closing price of $42.61

* The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 10 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)